{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T22:10:08Z","timestamp":1736719808587,"version":"3.32.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T00:00:00Z","timestamp":1168387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2007,1,30]]},"DOI":"10.1007\/s10620-006-9521-6","type":"journal-article","created":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T17:02:52Z","timestamp":1168362172000},"page":"442-450","source":"Crossref","is-referenced-by-count":11,"title":["A Randomized, Double-Blind, One-Week Study Comparing Effects of a Novel COX-2 Inhibitor and Naproxen on the Gastric Mucosa"],"prefix":"10.1007","volume":"52","author":[{"given":"James B.","family":"Moberly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart I.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S.","family":"Riff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Craig","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Breese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Truitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,1,10]]},"reference":[{"issue":"Suppl 1","key":"9521_CR1","first-page":"SI-13","volume":"69","author":"BN Cronstein","year":"2002","unstructured":"Cronstein BN (2002) Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med 69(Suppl 1):SI 13\u2013SI 19","journal-title":"Cleve Clin J Med"},{"key":"9521_CR2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","volume":"343","author":"MJ Langman","year":"1994","unstructured":"Langman MJ, Weil J, Wainwright P, et\u00a0al. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075\u20131078","journal-title":"Lancet"},{"issue":"28","key":"9521_CR3","first-page":"6","volume":"18","author":"JF Fries","year":"1991","unstructured":"Fries JF (1991) NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 18(28):6\u201310","journal-title":"J Rheumatol"},{"key":"9521_CR4","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"LS Simon","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, et\u00a0al. (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282:1921\u20131928","journal-title":"JAMA"},{"key":"9521_CR5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, et\u00a0al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247\u20131255","journal-title":"JAMA"},{"key":"9521_CR6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","volume":"96","author":"JL Goldstein","year":"2001","unstructured":"Goldstein JL, Correa P, Zhao WW, et\u00a0al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019\u20131027","journal-title":"Am J Gastroenterol"},{"key":"9521_CR7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","volume":"117","author":"L Laine","year":"1999","unstructured":"Laine L, Harper S, Simon T, et\u00a0al. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117:776\u2013783","journal-title":"Gastroenterology"},{"key":"9521_CR8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, et\u00a0al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102","journal-title":"N Engl J Med"},{"key":"9521_CR9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT, et\u00a0al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081\u20131091","journal-title":"N Engl J Med"},{"key":"9521_CR10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","volume":"365","author":"DJ Graham","year":"2005","unstructured":"Graham DJ, Campen D, Hui R, et\u00a0al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475\u2013481","journal-title":"Lancet"},{"key":"9521_CR11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.105.568451","volume":"112","author":"EA Antman","year":"2005","unstructured":"Antman EA, DeMets D, Loscalzo J (2005) Cyclooxygenase inhibitors and cardiovascular risk. Circulation 112:759\u2013770","journal-title":"Circulation"},{"key":"9521_CR12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1470-2045(01)00488-0","volume":"2","author":"A Dannenberg","year":"2001","unstructured":"Dannenberg A, Altorki NK, Boyle JO, et\u00a0al. (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544\u2013551","journal-title":"Lancet Oncol"},{"key":"9521_CR13","doi-asserted-by":"crossref","unstructured":"Cannon CP, Curtis SP, Bolognese JA, Laine L (2006) Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 152:237\u2013245.","DOI":"10.1016\/j.ahj.2006.05.024"},{"key":"9521_CR14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","volume":"41","author":"LS Simon","year":"1998","unstructured":"Simon LS, Lanza FL, Lipsky PE, et\u00a0al. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arth Rheum 41:1591\u20131602","journal-title":"Arth Rheum"},{"key":"9521_CR15","doi-asserted-by":"crossref","unstructured":"Oitate M, Hirota T, Koyama K, et\u00a0al. (2006) Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 34:1417\u20131422","DOI":"10.1124\/dmd.106.009860"},{"key":"9521_CR16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/0091270006287122","volume":"46","author":"H Kastrissios","year":"2006","unstructured":"Kastrissios H, Rohatagi S, Moberly J, et\u00a0al. (2006) Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor. J Clin Pharm 46:537\u2013548","journal-title":"J Clin Pharm"},{"key":"9521_CR17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","volume":"13","author":"FL Lanza","year":"1999","unstructured":"Lanza FL, Rack MF, Simon TJ, et\u00a0al. (1999) Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13:761\u2013767","journal-title":"Aliment Pharmacol Ther"},{"key":"9521_CR18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3565(24)38776-2","volume":"296","author":"D Riendeau","year":"2001","unstructured":"Riendeau D, Percival MD, Brideau C, et\u00a0al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558\u2013566","journal-title":"J Pharmacol Exp Ther"},{"key":"9521_CR19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0149-2918(01)80117-X","volume":"23","author":"SI Harris","year":"2001","unstructured":"Harris SI, Kuss M, Hubbard RC, Goldstein JL (2001) Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23:1422\u20131428","journal-title":"Clin Ther"},{"key":"9521_CR20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2036.2003.01691.x","volume":"18","author":"C Rordorf","year":"2003","unstructured":"Rordorf C, Kellett N, Mair S, et\u00a0al. (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18:533\u2013541","journal-title":"Aliment Pharmacol Ther"},{"key":"9521_CR21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/00365529709000182","volume":"32","author":"I Bjarnason","year":"1997","unstructured":"Bjarnason I, Macpherson A, Rotman H, et\u00a0al. (1997) A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32:126\u2013130","journal-title":"Scand J Gastroenterol"},{"key":"9521_CR22","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, et\u00a0al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520\u20131528","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9521_CR23","first-page":"SI-40","volume":"69","author":"JM Scheiman","year":"2002","unstructured":"Scheiman JM (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 69(Suppl 1):SI-40\u2013SI-46","journal-title":"Cleve Clin J Med"},{"key":"9521_CR24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF02265118","volume":"45","author":"C Brideau","year":"1996","unstructured":"Brideau C, Kargman S, Liu S, et\u00a0al. (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68\u201374","journal-title":"Inflamm Res"},{"key":"9521_CR25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","volume":"40","author":"A Van Hecken","year":"2000","unstructured":"Van Hecken A, Schwartz JI, Depre M, et\u00a0al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40:1109\u20131120","journal-title":"J Clin Pharmacol"},{"key":"9521_CR26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-3565(24)34895-5","volume":"290","author":"MR Panara","year":"1999","unstructured":"Panara MR, Renda G, Sciulli MG, et\u00a0al. (1999) Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 290:276\u2013280","journal-title":"J Pharmacol Exp Ther"},{"key":"9521_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.0306-5251.2001.01533.x","volume":"53","author":"H Blain","year":"2002","unstructured":"Blain H, Boileau C, Lapicque F, et\u00a0al. (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53:255\u2013265","journal-title":"Br J Clin Pharmacol"},{"key":"9521_CR28","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/BF01540567","volume":"35","author":"FL Lanza","year":"1990","unstructured":"Lanza FL, Graham DY, Davis RE, Rack MF (1990) Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 35:1494\u20131499","journal-title":"Dig Dis Sci"},{"key":"9521_CR29","first-page":"338","volume":"14","author":"F Lanza","year":"1987","unstructured":"Lanza F, Rack MF, Lynn M, et\u00a0al. (1987) An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 14:338\u2013341","journal-title":"J Rheumatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-006-9521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-006-9521-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-006-9521-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T21:45:38Z","timestamp":1736718338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-006-9521-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,30]]}},"alternative-id":["9521"],"URL":"https:\/\/doi.org\/10.1007\/s10620-006-9521-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2007,1,10]]}}}